Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.
复制标题

针对肺癌中PI3K/AKT/mTOR信号通路的研究进展:潜在药物与天然产物概述

DOI:
10.3390/molecules26134100
复制
发表时间:
2021-07-05
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
通讯作者:
Pongrakhananon V
Pongrakhananon V
中科院分区:
其他
文献类型:
--
作者:
Iksen;Pothongsrisit S;Pongrakhananon V

文献摘要

参考文献

被引文献

相似文献

肺癌是最常见的癌症之一,死亡率很高。由于其发病率高,该疾病的临床治疗仍然是一项重大挑战。多项报告已证实磷脂酰肌醇-3-激酶(PI3K)/蛋白激酶B(AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)通路与肺癌之间存在关联。该通路被视为肺癌的一个重要治疗靶点,主要是因为它在疾病的起始和进展过程中起着核心作用。近年来,人们对使用天然和合成药物靶向这些信号通路的兴趣日益增加,在体外、体内实验以及临床试验中均取得了有前景的结果。在这篇综述中,我们重点阐述目前对PI3K/AKT/mTOR信号通路在肿瘤发展中作用的认识。除了该信号通路外,我们还着重介绍了基于临床前和临床试验的、最新研发的PI3K/AKT/mTOR抑制剂的治疗潜力。
Lung cancer is one of the most common cancers and has a high mortality rate. Due to its high incidence, the clinical management of the disease remains a major challenge. Several reports have documented a relationship between the phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathway and lung cancer. The recognition of this pathway as a notable therapeutic target in lung cancer is mainly due to its central involvement in the initiation and progression of the disease. Interest in using natural and synthetic medications to target these signaling pathways has increased in recent years, with promising results in vitro, in vivo, and in clinical trials. In this review, we focus on the current understanding of PI3K/AKT/mTOR signaling in tumor development. In addition to the signaling pathway, we highlighted the therapeutic potential of recently developed PI3K/AKT/mTOR inhibitors based on preclinical and clinical trials.
DOI: 10.1016/s0092-8674(00)80595-4
发表时间: 1999-03-19
期刊: CELL
影响因子: 64.5
作者:
Brunet, A;Bonni, A;Greenberg, ME
通讯作者: Greenberg, ME
人类癌症中的磷酸肌醇3-激酶途径:遗传改变和治疗意义。
DOI: 10.2174/138920207782446160
发表时间: 2007-08
期刊: Current genomics
影响因子: 2.6
作者:
Arcaro A;Guerreiro AS
通讯作者: Guerreiro AS
DOI: 10.18632/oncotarget.14729
发表时间: 2017-03-28
期刊: Oncotarget
影响因子: --
作者:
Cai Y;Dodhia S;Su GH
通讯作者: Su GH
DOI: 10.1038/labinvest.2016.77
发表时间: 2016-09-01
影响因子: 5
作者:
Attar-Schneider, Oshrat;Drucker, Liat;Gottfried, Maya
通讯作者: Gottfried, Maya
DOI: 10.1038/cdd.2017.161
发表时间: 2018-01
影响因子: 12.4
作者:
Adams JM;Cory S
通讯作者: Cory S